OncRef
Skip to newsletter content
|
SCLCOctober 2026
0:00 / 4:02
Small Cell Lung Cancer — Monthly Compass
Oct 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
small cell lung cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • Maintenance tarlatamab‑dlle plus durvalumab (DeLLphi‑305) delivered a large overall survival and progression‑free survival advantage versus durvalumab alone in first‑line extensive‑stage SCLC without progression after induction chemo‑IO, positioning a new maintenance standard and accelerating global regulatory engagement.
    • FDA withdrew the accelerated approval for Zepzelca (lurbinectedin) in metastatic SCLC after confirmatory phase 3 LAGOON failed to show an overall survival benefit, removing this previously treated option while leaving the separate maintenance ES‑SCLC indication with atezolizumab unaffected.
  • Important Drug Publication Updates
    • The New England Journal of Medicine published DeLLphi‑305 on October 24, 2026, reporting that tarlatamab–durvalumab maintenance improved survival endpoints compared with durvalumab alone in first‑line extensive‑stage SCLC.
  • Key Clinical Development Updates
    • Daiichi Sankyo and Merck voluntarily withdrew the BLA for ifinatamab deruxtecan in previously treated ES‑SCLC after FDA discussions concluded the data, including IDeate‑Lung01, did not meet accelerated approval requirements despite Priority Review, RTOR, and Project Orbis status with an October 10, 2026 PDUFA date, while phase 3 IDeate‑Lung02 enrollment continues with a potential future filing based on its results.
    • Following successful FDA Type C meetings and updated ESMO 2026 data, IDEAYA plans two global phase 3 registrational trials of the DLL3 TOP1 ADC IDE849 in post‑Imdelltra ES‑SCLC and NEC and is evaluating a first‑line ES‑SCLC phase 3 design.
  • Important Clinical Trial Publications
    • Extended DeLLphi‑304 follow‑up in previously treated SCLC demonstrated durable survival benefit with tarlatamab and early, manageable CRS/ICANS, informing clinical workflows for this setting.
  • Key Conference Updates
    • At ESMO 2026 (October 23–27, Madrid), DLL3 and B7‑H3 programs advanced as obrixtamig (BI 764532) plus topotecan maintained PFS despite reduced chemotherapy intensity and ADCs—risvutatug rezetecan and zocilurtatug pelitecan—showed anti‑tumor activity with a global phase 3 EMBOLD‑SCLC‑301 announced and chemo‑sparing backbones prioritized.
    • CHEST 2026 real‑world data on tarlatamab reported predominantly grade 1–2 CRS with no grade 3–4 events in cycle 1, supporting safe implementation pathways and potential outpatient models after initial monitoring.
  • Emerging Themes & Macro-Trends
    • DLL3 and B7‑H3 targeting via T‑cell engagers and Topo‑I ADCs is driving a chemo‑sparing paradigm in ES‑SCLC, with calibrated cytotoxic intensity (e.g., attenuated topotecan with DLL3 TCEs) and careful ILD monitoring plus avoidance of myelosuppressive triplets to sustain exposure.
    • Standardized CRS preparedness—anchored in predictable early‑cycle kinetics and prophylactic steroid/tocilizumab algorithms—is becoming essential to expand access across community and academic centers and to reduce ICU utilization.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-10-01 and 2026-10-31 about small cell lung cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Daiichi Sankyo and Merck voluntarily withdrew their BLA for ifinatamab deruxtecan (I‑DXd) in previously treated ES‑SCLC following an FDA discussion that the data (including IDeate‑Lung01) did not meet accelerated approval requirements; the filing had been under Priority Review, RTOR, and Project Orbis with an October 10, 2026 PDUFA date. The partners said phase 3 IDeate‑Lung02 enrollment would continue, with the possibility of a future FDA filing based on those results. ¹ (read more)
  • FDA withdrew the accelerated approval for Zepzelca (lurbinectedin) in metastatic SCLC after confirmatory phase 3 LAGOON results failed to show an overall survival benefit; this change, effective September 30, 2026, does not affect the separate maintenance ES‑SCLC indication with atezolizumab. The article reiterates the prior accelerated approval basis and the label status following the withdrawal. ² (read more)
  • IDEAYA Biosciences reported updated ESMO 2026 data for IDE849 (SHR‑4849), a DLL3 TOP1 ADC, and stated that, following successful FDA Type C meetings, it is targeting initiation of two global phase 3 registrational trials in ES‑SCLC (post‑Imdelltra) and NEC. The company also noted it is evaluating a potential first‑line ES‑SCLC phase 3 study design, reflecting ongoing FDA regulatory‑meeting guidance. ³ (read more)
Conference
Major Conference Updates
Conference Information
  • European Society for Medical Oncology (ESMO) Congress 2026, Madrid, Spain; October 23–27, 2026. (read more)
  • CHEST Annual Meeting 2026, Phoenix, Arizona; October 18–21, 2026. (read more)
  • Overall sentiment: DLL3-directed T‑cell engagers and ADCs dominated SCLC with practice-changing first‑line maintenance data and credible chemo‑sparing signals, while real‑world experience refined safety operations for wider access. (read more)
  • Theme 1: DLL3 T‑Cell Engagers Reframe Care (Maintenance + Post‑Platinum)
    • Significance: First-line maintenance “tarlatamab‑dlle + durvalumab” (DeLLphi‑305) delivered a large OS and PFS advantage vs durvalumab alone, positioning a new maintenance standard and accelerating regulatory engagement. (read more)
    • Mechanism insights / clinical impact: DLL3×CD3 T‑cell engagement yielded durable disease control and lower high‑grade toxicity vs chemotherapy in relapsed SCLC (extended DeLLphi‑304), with CRS/ICANS generally early and manageable—informing clinic workflows. (read more)
    • Patient populations affected: ES‑SCLC without progression after induction chemo‑IO (1L maintenance) and previously treated ES‑SCLC; benefit observed across clinically relevant subgroups, including patients with brain metastases. (read more)
  • Theme 2: Operationalization and Access—CRS Management Enables Broader Use
    • Significance: Real‑world tarlatamab experience at CHEST 2026 showed predominantly grade 1–2 CRS and no grade 3–4 events in cycle 1, supporting safe implementation pathways and potential for outpatient models after initial monitoring. (read more)
    • Mechanism insights / clinical impact: Early‑cycle cytokine biology drives predictable CRS kinetics; prophylactic steroids/tocilizumab algorithms minimize escalation, reducing ICU utilization and standardizing site activation. (read more)
    • Patient populations affected: Relapsed ES‑SCLC treated with DLL3 TCEs at community and academic centers; older/comorbid patients where streamlined monitoring can expand access. (read more)
  • Theme 3: ADC Renaissance and Chemo‑Sparing First‑Line Strategies
    • Significance: B7‑H3 ADC “risvutatug rezetecan (Ris‑Rez)” showed anti‑tumor activity in ES‑SCLC with pooled ILD surveillance and a global phase 3 (EMBOLD‑SCLC‑301) program announced; DLL3 ADC “zocilurtatug pelitecan (zoci)” produced high 1L ORR with an IO doublet and signaled greater toxicity when adding platinum—supporting chemo‑sparing backbones. (read more)
    • Mechanism insights / clinical impact: Cell‑surface antigen targeting (B7‑H3, DLL3) coupled to Topo‑I payloads delivers deep responses; careful ILD monitoring and avoidance of myelosuppressive triplets may sustain exposure and CNS control potential. (read more)
    • Patient populations affected: 1L ES‑SCLC (zoci + atezolizumab ± carboplatin) and relapsed ES‑SCLC (EMBOLD‑SCLC‑301, DLLEVATE) across global geographies. (read more)
  • Theme 4: Calibrating Chemo Intensity in DLL3 Combinations
    • Significance: At ESMO, obrixtamig (BI 764532) + topotecan maintained PFS despite lower chemo dose intensity, suggesting DLL3 TCEs can buffer reduced cytotoxic dosing without efficacy loss. (read more)
    • Mechanism insights / clinical impact: Synergy between T‑cell engagement and DNA‑damaging agents enables response even with attenuated topotecan, informing tolerability‑focused regimens. (read more)
    • Patient populations affected: Second‑line ES‑SCLC where frailty or hematologic reserve limits full‑dose topotecan. (read more)
  • Significance
    • Expected clinical or translational readouts: Final OS updates and subgroup biomarker analyses from DeLLphi‑305; initiation of global phase 3 for zoci 1L ES‑SCLC; EMBOLD‑SCLC‑301 progress; additional DLL3 combo datasets. (read more)
    • Regulatory or policy implications: Amgen indicated plans to engage regulators globally on DeLLphi‑305, foreshadowing rapid label expansion in 1L maintenance. (read more)
    • Potential shifts in standard of care: Maintenance tarlatamab‑dlle + durvalumab poised to redefine 1L ES‑SCLC; ADC‑IO doublets could challenge platinum‑based induction in select patients. (read more)
    • Strategic implications: Intensifying competition across DLL3 TCEs and DLL3/B7‑H3 ADCs; partnership ecosystems (e.g., zoci + tarlatamab/obrixtamig) enable multi‑target backbones; sites should invest in CRS pathways to unlock adoption at scale. (read more)
Publications Related to Approved Drugs
There are no new publication updates during the 2026-10-01 to 2026-10-31 for small cell lung cancer.
New Publications Related to Drugs in Clinical Trial Development
Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. Sofetabart mipitecan (Sofe-M), a novel FRα-targeting ADC, demonstrated durable clinical activity (ORR 50.5%) and a favorable tolerability profile, notably lacking keratopathy, in heavily pretreated high-grade ovarian cancer patients, irrespective of FRα expression or prior MIRV treatment. The study established 3 mg/kg as the recommended phase 3 dose, providing the basis for the FRAmework-01 trial. () .
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial. The first-in-class, bispecific dual T cell agonist invikafusp alfa demonstrated an acceptable safety profile and preliminary anti-tumor activity in patients with mostly immune checkpoint blockade-resistant solid tumors. At the optimal biological doses, the overall objective response rate was 14.8%, including responses in immunologically cold tumors like microsatellite stable colorectal cancer, supporting 0.08 mg/kg as the recommended phase 2 dose. () .
Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol. This phase II trial protocol outlines a study to evaluate if adding the RANKL inhibitor narlumosbart and stereotactic body radiation therapy (SBRT) to first-line chemoimmunotherapy can improve efficacy in advanced NSCLC patients with bone metastases. The primary endpoint is the objective response rate of non-irradiated lesions, based on the hypothesis that this combination can synergistically modulate the immunosuppressive tumor microenvironment. () .
Adebrelimab combined with apatinib and chemotherapy for neoadjuvant therapy and biomarker analysis in limited-stage small cell lung cancer: study protocol for a single-arm trial. This phase II trial protocol details an investigation into a novel neoadjuvant regimen combining adebrelimab (anti-PD-L1), apatinib (VEGFR2 inhibitor), and chemotherapy for patients with resectable limited-stage SCLC. The primary endpoint is the 2-year event-free survival rate, with extensive biomarker analyses planned to explore mechanisms of response and resistance. () .
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. The combination of osimertinib plus gefitinib demonstrated only modest clinical benefit in patients with EGFR-mutated advanced NSCLC who developed a C797X resistance mutation after first-line osimertinib. With a confirmed objective response rate of 26% and a median progression-free survival of 5.1 months, the risk-benefit profile does not warrant further evaluation of this regimen in this specific patient population. () .
Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671. In a subgroup analysis of the KEYNOTE-671 study, Japanese participants with early-stage NSCLC showed improved efficacy with perioperative pembrolizumab plus neoadjuvant chemotherapy compared to chemotherapy alone. The findings, including a 48-month event-free survival rate of 60.3% vs. 39.2%, were consistent with the global study and support the use of this regimen in Japanese patients. () .
Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. The KEYVIBE-008 study, evaluating the anti-TIGIT antibody vibostolimab with pembrolizumab and chemotherapy for first-line extensive-stage SCLC, was discontinued after meeting a prespecified futility criterion for overall survival at an interim analysis. The combination also resulted in a higher frequency of Grade ≥3 treatment-related adverse events compared to the atezolizumab plus chemotherapy control arm. () .
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China. The novel HER3-directed antibody-drug conjugate ruzaltatug rezetecan significantly prolonged progression-free survival compared to standard chemotherapy (median 8.3 vs. 5.4 months) in patients with EGFR-mutated advanced NSCLC resistant to EGFR-TKI therapy. These phase 3 interim results, coupled with a manageable safety profile, support ruzaltatug rezetecan as a potential new treatment option in this setting. () .
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. The first-in-class EGFR-HER3 bispecific antibody-drug conjugate, Izalontamab brengitecan (iza-bren), demonstrated encouraging antitumor activity in relapsed extensive-stage SCLC, with an overall response rate of 48.1%. Notably, in the second-line setting, the ORR was 72.7% with a median OS of 15.0 months, supporting its ongoing evaluation in a phase III trial. () .
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. In the CheckMate 77T study, pre-surgical clearance of circulating tumor DNA (ctDNA) and achieving a pathologic complete response (pCR) were identified as key predictors of prolonged event-free survival (EFS) with perioperative nivolumab in resectable NSCLC. The findings also suggest that nivolumab may provide an EFS benefit in patients with specific driver gene co-alterations (KEAP1, STK11, CDKN2A, SMARCA4), offering insights into predictive markers for this treatment regimen. () .
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2. In the NeoCOAST-2 phase 2 trial for resectable NSCLC, neoadjuvant treatment with chemotherapy, durvalumab, and datopotamab deruxtecan (Dato-DXd) resulted in the highest rate of circulating tumor DNA (ctDNA) clearance. The study established a strong correlation between ctDNA clearance and prolonged event-free survival, suggesting that the combined assessment of ctDNA and pathological complete response may improve risk stratification. () .
Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. In the phase 3 SAFFRON trial, the combination of osimertinib and the MET-TKI savolitinib resulted in significantly longer progression-free survival (HR 0.55) and overall survival (HR 0.68) compared to platinum-pemetrexed chemotherapy. This establishes the combination as a new standard of care for patients with EGFR-mutated, MET-amplified/overexpressed advanced NSCLC that has progressed on osimertinib. () .
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. In patients with unresectable stage III NSCLC treated with chemoradiotherapy followed by durvalumab, the detection of circulating tumor DNA (ctDNA) during and after durvalumab consolidation was strongly associated with a significantly higher risk of progression and shorter progression-free survival. These findings suggest that serial ctDNA-based minimal residual disease (MRD) assessment can identify high-risk patients who may benefit from intensified treatment strategies. () .
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. The addition of neoadjuvant, concurrent, and adjuvant atezolizumab to stereotactic body radiation therapy (SBRT) did not improve overall survival in patients with high-risk, medically inoperable, early-stage NSCLC. The trial was closed for futility at the first interim analysis, indicating this immunotherapy combination is not beneficial in this setting and was associated with a higher rate of grade 3 or higher adverse events. () .
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). In patients with treatment-naïve advanced NSCLC and high PD-L1 expression (≥50%), first-line treatment with pembrolizumab plus platinum-based chemotherapy significantly prolonged progression-free survival compared to pembrolizumab monotherapy (16.1 vs. 6.9 months). This head-to-head comparison demonstrates that the combination therapy provides superior efficacy, albeit with a higher incidence of grade ≥3 adverse events. () .
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study. The combination of encorafenib and binimetinib demonstrated significant clinical benefit in Chinese participants with BRAFV600E-mutated metastatic NSCLC, achieving a confirmed objective response rate of 61% by independent central review. With a median progression-free survival of 13.8 months and a manageable safety profile, these data confirm the efficacy of this targeted therapy combination in this specific patient population. () .
Selpercatinib in Pediatric and Adolescent Patients With <i>RET</i>-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. The selective RET inhibitor selpercatinib demonstrated durable efficacy and was well tolerated in pediatric and adolescent patients with RET-altered solid tumors, primarily thyroid cancers. The study reported an objective response rate of 53% by independent review, with a 24-month duration of response rate of 100%, supporting the use of selpercatinib for targeting RET alterations in this younger patient population. () .
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. In patients with previously untreated, PD-L1-negative advanced nonsquamous NSCLC, first-line treatment with the TROP2-ADC sacituzumab tirumotecan plus pembrolizumab significantly improved progression-free survival compared to standard chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). These phase 3 results suggest a promising new chemotherapy-free regimen for this patient population, with immature but favorable overall survival data. () .
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China. The first-in-class EGFR-HER3 bispecific antibody-drug conjugate, izalontamab brengitecan (iza-bren), significantly prolonged progression-free survival compared to platinum-based chemotherapy (median 11.1 vs. 5.7 months) in patients with EGFR-mutated NSCLC after progression on third-generation EGFR TKIs. This phase 3 trial provides the first evidence for a bispecific ADC in this setting, establishing iza-bren as a potential new treatment option despite a higher frequency of grade 3 or worse adverse events. () .
Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. The irreversible EGFR-TKI sutetinib demonstrated clinically meaningful antitumor activity in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations (G719X, S768I, L861Q). The trial met its primary endpoint with a confirmed objective response rate of 70.8% and a median progression-free survival of 13.7 months, supporting its use as a potential first-line option for this molecularly diverse population. () .
Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. This study demonstrates that a plasma-based cfChIP-seq liquid biopsy platform can non-invasively capture the epigenetic landscape of SCLC, allowing for real-time assessment of tumor burden and inference of critical transcriptional subtypes (e.g., ASCL1, NEUROD1). This technology offers a promising tool for precision monitoring and subtype-driven therapeutic strategies in a disease where tissue biopsies are often limited. () .
InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer. The InDuRanS phase II trial protocol describes the first randomized study designed to directly compare surgery versus definitive chemoradiotherapy (CRT) following neoadjuvant immunochemotherapy in patients with stage IIB-IIIA/B NSCLC. The primary endpoint is 2-year event-free survival, and its results are expected to define optimal local treatment strategies in this evolving therapeutic landscape. () .
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. The first-in-class EGFR-HER3 bispecific antibody-drug conjugate, Izalontamab brengitecan (iza-bren), demonstrated encouraging antitumor activity in relapsed extensive-stage SCLC, with an overall response rate of 48.1%. Notably, in the second-line setting, the ORR was 72.7% with a median OS of 15.0 months, supporting its ongoing evaluation in a phase III trial. () .
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial. The phase 2 MDT-BRIDGE study demonstrated the feasibility of a multidisciplinary team-guided approach using neoadjuvant durvalumab plus chemotherapy for resectable and borderline resectable NSCLC. This strategy enabled a high overall resection rate (74.6%) and allowed most patients to proceed to curative-intent treatment (surgery or chemoradiotherapy) followed by consolidation durvalumab, with a manageable safety profile. () .
Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study. The FRα-targeting antibody-drug conjugate farletuzumab ecteribulin (FZEC) was associated with a significant risk of interstitial lung disease (ILD)/pneumonitis in patients with advanced solid tumors. The study found that fractionated dosing (8 mg/m² on D1/D8/D15) appeared to reduce the risk of ILD and showed preliminary antitumor activity, warranting further investigation of this schedule. () .
TP53 Y220C hotspot mutation in clinically advanced ovarian carcinoma: Frequency and genomic features. A large-scale genomic analysis revealed that the potentially targetable TP53 Y220C hotspot mutation occurs in 2.9% of clinically advanced ovarian carcinomas, making it one of the most frequent tumor types to harbor this alteration. This finding is clinically relevant as novel drugs like Rezatapopt are being developed to restore wild-type function to this specific mutant, highlighting a potential therapeutic opportunity for this subset of patients. () .
A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer. The c-Met targeting antibody-drug conjugate telisotuzumab adizutecan (Temab-A) in combination with bevacizumab demonstrated a favorable risk-benefit profile and clinically meaningful efficacy improvements over standard-of-care in heavily pretreated metastatic colorectal cancer. The 2.4 mg/kg dose showed an objective response rate of 30% (vs 0% for control) and improved survival outcomes, supporting its evaluation in a global Phase 3 trial. () .
At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study. This small feasibility study demonstrated that at-home, nurse-administered subcutaneous atezolizumab for NSCLC patients is feasible, safe, and associated with high patient satisfaction. The at-home setting also resulted in a shorter measured administration duration compared to in-clinic treatment, suggesting a potential to reduce patient burden. () .
Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. The anti-PD-1/TIGIT bispecific antibody rilvegostomig showed a favorable tolerability profile but limited clinical efficacy in heavily pretreated, PD-L1-positive metastatic NSCLC patients. At the recommended phase II dose of 750 mg, the objective response rate was 5.6% and median progression-free survival was 3.8 months, supporting further evaluation in checkpoint inhibitor-naïve populations. () .
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial. The combination of an intratumoral CCL21-expressing dendritic cell vaccine with pembrolizumab was well tolerated but did not meet its primary endpoint for objective response rate in advanced NSCLC. While the therapy increased T cell infiltration into tumors, this did not translate into clinical efficacy, potentially due to the limited persistence of novel T cell clones and an immunosuppressive myeloid microenvironment. () .
Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. The mutant-selective EGFR TKI firmonertinib demonstrated significant clinical activity as a first-line treatment for patients with NSCLC harboring EGFR P-loop and αC-helix compressing (PACC) mutations, a subgroup with limited options. In a phase 1b study, the 240 mg dose achieved a confirmed objective response rate of 68% and a median progression-free survival of 16.0 months, supporting further investigation in this population. () .
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. In a phase 3 trial for relapsed SCLC after platinum-based therapy, the B7-H3 targeting antibody-drug conjugate tambotatug pelitecan significantly improved median overall survival to 13.3 months versus 9.4 months for topotecan. The treatment also demonstrated superior progression-free survival (7.4 vs 2.8 months) and a higher objective response rate (59.1% vs 9.7%) with a more favorable safety profile. () .
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib. The type II ROS1/MET TKI cabozantinib demonstrated clinical activity in heavily pre-treated ROS1 fusion-positive NSCLC patients who had developed resistance to type I inhibitors. The study achieved an overall response rate of 43%, including responses in patients with multi-drug-resistant mutations like ROS1 G2032R, highlighting the potential utility of type II ROS1 inhibition in later-line settings. () .
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. The chemotherapy-sparing combination of amivantamab, lazertinib, and bevacizumab demonstrated durable anti-tumor activity in patients with EGFR-mutant NSCLC who progressed on a third-generation EGFR TKI. The phase 2 trial reported a 12-week objective response rate of 33% and an overall response rate of 39%, presenting a promising alternative to chemotherapy-based regimens in this setting. () .
Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. First-line maintenance therapy with the DLL3xCD3 BiTE tarlatamab plus durvalumab resulted in a significant and clinically meaningful improvement in overall survival for patients with extensive-stage SCLC, with a median OS of 21.1 months compared to 12.7 months for durvalumab alone. This combination also markedly improved progression-free survival (7.4 vs 1.9 months), establishing a new potential standard of care in the maintenance setting. () .
Divarasib as Compared with Sotorasib or Adagrasib in <i>KRAS</i> G12C-Mutated NSCLC. The next-generation KRAS G12C inhibitor divarasib led to significantly longer progression-free survival (9.8 vs. 5.7 months) and overall survival (17.7 vs. 12.0 months) compared to first-generation inhibitors (sotorasib/adagrasib) in previously treated KRAS G12C-mutated NSCLC. This phase 3 trial establishes divarasib as a more effective treatment option with a favorable safety profile in this patient population. () .
Nivolumab and cabozantinib in people with HIV and advanced solid tumors: a pilot trial and systematic review. In a pilot trial for people living with HIV (PWH) and advanced solid tumors, the combination of nivolumab and cabozantinib demonstrated a manageable safety profile without compromising HIV virologic control. While efficacy could not be determined from the small cohort, durable disease stabilization was observed in several heavily pretreated participants, supporting larger dedicated studies of this combination in PWH. () .
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study. The HYPERBOLIC phase 2 trial protocol describes a biomarker-driven study to investigate if adding three cycles of platinum-based chemotherapy to first-line cemiplimab can reduce the rate of hyperprogressive disease (HPD) in NSCLC patients with PD-L1 ≥ 50% and high baseline levels of circulating immature neutrophils. This is the first prospective trial designed to test an early treatment escalation strategy based on a biomarker for HPD risk. () .
Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung Cancer in China. Based on data from the ORIENT-3 trial, sintilimab was found to be a cost-effective second-line therapy for advanced squamous NSCLC in China compared to docetaxel. Sintilimab provided an additional 0.32 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio of $8,717.25 per QALY, which is below China's willingness-to-pay threshold. () .
ENTRÉE Lung: An Open-label Platform Study Investigating the Safety and Pharmacokinetics of Belrestotug Combinations in Advanced Non-Small Cell Lung Cancer. The combination of dostarlimab (anti-PD-1) and belrestotug (anti-TIGIT), with or without nelistotug (anti-CD96), was well tolerated but demonstrated no clinically meaningful activity in patients with advanced NSCLC who had progressed on prior anti-PD-(L)1 and platinum-based therapy. The lack of efficacy suggests that further research is needed to identify patient populations who might benefit from such immunotherapy combinations. () .
Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. This study demonstrates that a plasma-based cfChIP-seq liquid biopsy platform can non-invasively capture the epigenetic landscape of SCLC, allowing for real-time assessment of tumor burden and inference of critical transcriptional subtypes (e.g., ASCL1, NEUROD1). This technology offers a promising tool for precision monitoring and subtype-driven therapeutic strategies in a disease where tissue biopsies are often limited. () .
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study. The addition of the LAG-3 inhibitor relatlimab to nivolumab plus chemotherapy did not significantly improve the objective response rate in the overall first-line advanced NSCLC population. However, a trend towards improved clinical benefit was observed in the subgroup of patients with nonsquamous histology and PD-L1 ≥1%, supporting further investigation of this combination in that specific population. () .
A Max 0-1 Weighted Log-Rank Test for Time-to-Event Data With Random Delayed Treatment Effect. This paper proposes a new statistical testing method, a Max 0-1 weighted log-rank test, designed to provide more optimal power for analyzing time-to-event data in clinical trials where the treatment effect is delayed, such as with immunotherapies. The method's utility was demonstrated through simulation studies and by re-analyzing data from a non-small-cell lung cancer clinical trial. () .
Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. This study demonstrates that a plasma-based cfChIP-seq liquid biopsy platform can non-invasively capture the epigenetic landscape of SCLC, allowing for real-time assessment of tumor burden and inference of critical transcriptional subtypes (e.g., ASCL1, NEUROD1). This technology offers a promising tool for precision monitoring and subtype-driven therapeutic strategies in a disease where tissue biopsies are often limited. () .
Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib. In the phase II LUCAS study, continuing the EGFR TKI lazertinib and adding platinum-pemetrexed chemotherapy after progression on prior lazertinib demonstrated meaningful systemic and intracranial activity. This strategy resulted in a median progression-free survival of 9.5 months and an objective response rate of 36.0%, suggesting a clinical benefit to continuing EGFR inhibition with chemotherapy in this setting. () .
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in small cell lung cancer updated from 2026-10-01 to 2026-10-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting551737239
Recruiting4652609383208
Available-------
Approved for Marketing-------
Active, Not Recruiting231428521192
Completed-15-3-9
Total747211017696348
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Cisplatin, Cetuximab, PF-07934040, pemetrexed, Bevacizumab, Paclitaxel, Nab-paclitaxel, Fluorouracil, Leucovorin, Carboplatin, Gemcitabine, Pembrolizumab, Sasanlimab, Oxaliplatin NCT06447662 ACTIVE_NOT_RECRUITING A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene 2026-10-09
Mobocertinib NCT03807778 ACTIVE_NOT_RECRUITING A Phase 1/2 Study of the Oral EGFR/HER2 Inhibitor TAK-788 in Japanese Non-Small Cell Lung Cancer Patients 2026-10-28
Part B - AZD9291 in combination with selumetinib, Part D - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part A - AZD9291 in combination with AZD6094, Part C - AZD9291 in combination with AZD6094 (Japan only), Part A - AZD9291 in combination with MEDI4736, Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part B - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects) NCT02143466 ACTIVE_NOT_RECRUITING A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON). 2026-12-31
[89Zr]Zr-BI 764532, BI 764532 NCT05963867 RECRUITING An Open-label Phase 1 PET Imaging Trial to Investigate [89Zr]Zr-BI 764532 Biodistribution and Tumour Uptake in Patients With Small-cell Lung Carcinoma or Neuroendocrine Carcinoma 2027-01-15
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Lazertinib/Pemetrexed/Carboplatin NCT05786430 COMPLETED Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS) 2026-08-23
JS004, Platinum, Etoposide, Toripalimab NCT06648200 COMPLETED Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer: a Single-center, Randomized Trial 2026-08-29
Pemetrexed, Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin, Pembrolizumab NCT04736173 COMPLETED Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer 2026-09-17
Durvalumab NCT03999710 COMPLETED Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART) 2026-10-20
JDQ443 NCT05445843 ACTIVE_NOT_RECRUITING KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. 2026-10-28
Nab paclitaxel, BGB-15025, Cisplatin, LBL-007, pemetrexed, Paclitaxel, Tislelizumab, Carboplatin, BGB-A445 NCT05635708 COMPLETED Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer 2026-10-29
Durvalumab, Tremelimumab, Paclitaxel, Carboplatin NCT03965468 ACTIVE_NOT_RECRUITING A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer 2026-12
: Pembrolizumab NCT04032418 ACTIVE_NOT_RECRUITING Randomized Phase II Study of Pembrolizumab 200mg every12 Weeks Versus Every 3 Weeks in NSCLC With Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study 2026-12-14
[No Drug Info] NCT06660407 ACTIVE_NOT_RECRUITING Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition 2027-01-10
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
HS-20093, Topotecan NCT06498479 COMPLETED ARTEMIS-008:A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy 2026-08-20
: Pembrolizumab SC, : Pembrolizumab IV, Cisplatin, Pemetrexed, Paclitaxel, Nab-Paclitaxel, Carboplatin NCT04956692 COMPLETED A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer 2026-08-24
Pemetrexed, Carboplatin, Cisplatin, TAK-788 NCT04129502 COMPLETED A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations 2026-09-22
Osimertinib, Ramucirumab, Erlotinib, Gefitinib NCT02411448 ACTIVE_NOT_RECRUITING A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer 2026-12
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.